Henry Stewart Talks

The Biomedical & Life Sciences Collection

Online Seminars By Leading World Experts
Search

Talk: Manufacturing viral gene therapy vectors: general ap... (36 min)

 Loading...

This talk is not yet available, however should be within a few days.

We apologize for the inconvenience.

- Henry Stewart Talks

We hope you have enjoyed this free, full length talk

  • Would you like to recommend that your librarian or other responsible officer takes out a subscription to The Biomedical & Life Sciences Collection?
  • Would you like to apply for a free trial of the entire Biomedical & Life Sciences Collection?
Recommend to Librarian       Apply for Free Trial       Replay Talk

SHARE THIS TALK

Email via Local Program (e.g. Outlook) Email via the Web Share with Facebook Tweet on Twitter Share with Gmail Share with VKontakte Share with LinkedIn More

DETAILED SLIDE INDEX

  1. 1. Introduction
  2. 2. Natural virus life cycle
  3. 3. Production of injectable viral vectors
  4. 4. Production of viral vectors for ex vivo transduction
  5. 5. Engineering vector producer cells
  6. 6. Stable vector producer cells
  7. 7. Transient vector producer cells
  8. 8. Summary of terminology
  9. 9. Design strategies for engineering helper cassettes
  10. 10. The basic biology of the virus
  11. 11. Idealized vector production system
  12. 12. Organization of a vector system
  13. 13. Goals for the design of a production system
  14. 14. Individual vector production systems
  15. 15. Adenoviral vectors
  16. 16. First generation adenovirus vector production
  17. 17. Minimally deleted adenovirus vectors
  18. 18. Helper dependent adenovirus vector production (1)
  19. 19. Helper dependent adenovirus vector production (2)
  20. 20. Retroviral vectors
  21. 21. Moloney Murine Leukemia Virus
  22. 22. Stable cell lines
  23. 23. Self-inactivating retroviral vector genomes
  24. 24. SIN retroviral vector production
  25. 25. HIV based lentiviral vectors
  26. 26. HIV based lentiviral vector systems
  27. 27. Lentiviral vector production
  28. 28. Lentiviral stable cell lines
  29. 29. AAV vector & helper components
  30. 30. Adenovirus genome - 35,935 bp
  31. 31. Plasmid-based AAV vector production
  32. 32. Dedicated AAV producer cells
  33. 33. Baculovirus-based AAV vector production
  34. 34. Pseudoreplication
  35. 35. Downstream processing (1)
  36. 36. Downstream processing (2)
  37. 37. Cleanroom management
  38. 38. Product testing (1)
  39. 39. Product testing (2)
  40. 40. Example release testing for AAV vector product
  41. 41. Final remarks
  42. 42. END

RELATED TALKS

Play 'Directed evolution of novel adeno-associated viral vectors for gene therapy'
Directed evolution of novel adeno-associated viral vectors for gene therapy More info
Prof. David Schaffer
UG 

TOPICS COVERED IN THIS TALK

  • Recent successes in gene therapy
  • Problems in the field with naturally derived vectors
  • Directed evolution as an approach to engineer optimal viral vector variants that meet clinical needs
  • Examples: development of variants to evade neutralizing antibodies and evolution for enhanced delivery in the retina
Play 'Helper-dependent adenoviral vectors for gene therapy'
Helper-dependent adenoviral vectors for gene therapy More info
Prof. Nicola Brunetti-Pierri

TOPICS COVERED IN THIS TALK

  • Overview of gene therapy vectors
  • Helper-Dependent Ad (HDAd) vector
  • Liver and lung directed gene therapy
  • Hemophilia B gene therapy
  • OTC deficiency clinical trial
  • Balloon occlusion catheter-based delivery of HDAd
  • HDAd-mediated CF gene therapy
  • Brain gene therapy
  • HDAd as genetic vaccine
  • HDAd and stem cells
Play 'Gene therapy and gene transfer: vector integration preferences and integration site analysis'
Gene therapy and gene transfer: vector integration preferences and integration site analysis More info
Prof. Frederic Bushman

TOPICS COVERED IN THIS TALK

  • Introduction: human gene therapy with integrating vectors
  • Methods for monitoring gene transfer
  • HIV integration targeting
  • Gammaretroviral integration targeting
  • Analysis of vector integration in human gene therapy
Play 'The host response: adaptive immune response to viral vector delivery'
The host response: adaptive immune response to viral vector delivery More info
Prof. Roland W. Herzog
UG 

TOPICS COVERED IN THIS TALK

  • Gene therapy using viral vector
  • Risk of immune responses specific to vector or transgene product
  • Pre-existing immunity to viral vectors due to natural infection
  • Design of vectors to minimize or entirely avoid B and T cell responses
  • Modification of gene transfer protocols to minimize/avoid/circumvent B and T cell responses
Play 'Gene therapy for the muscular dystrophies'
Gene therapy for the muscular dystrophies More info
Prof. Jeff Chamberlain

TOPICS COVERED IN THIS TALK

  • Introduction to the muscular dystrophies
  • Duchenne muscular dystrophy (DMD)
  • Dystrophin, the gene product of the DMD locus
  • The molecular basis of DMD
  • Strategies for the development of DMD therapies
  • Adeno-associated viral (AAV) vectors and micro-dystrophins
  • Scaling gene therapies to large animal models
  • Exon skipping therapies

USE THIS TALK IN YOUR COURSE

TALK'S CITATION

Gray, J.T. (2014), "Manufacturing viral gene therapy vectors: general approaches and challenges", in Naldini, L. (ed.), Gene Transfer and Gene Therapy: , The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London (online at http://hstalks.com/?t=BL1843763)

RELATED SERIES

The Legacy of Drosophila Genetics
From 'defining the gene' to 'analyzing genome function'
Gene-Environment Interactions
Role in the Modulation of Pulmonary and Autoimmune Disease Risks
Eukaryotic Gene Regulation
From Chromatin to Transcription to mRNA Processing
Antibiotic Resistance
From genes to global prevalence
Cancer Therapy
Latest thinking in efficacy and toxicity
Welcome, Guest
Login  
Apply for Free Trial Recommend to Librarian Keep Me Updated

ABOUT THIS TALK

Speaker(s)

Prof. John T. Gray Show Biography

SPEAKER BIOGRAPHY

Prof. John T. Gray – Audentes Therapeutics Inc., USA

John Gray is the Vice President of Research & Development at Audentes Therapeutics, a biotechnology company committed to the development and commercialization of novel gene therapies for people with serious, rare diseases. He received his undergraduate degree in biochemistry at the University of California, Berkeley, and Ph.D. from the University of Colorado, Boulder. He has been working on the design and manufacturing of engineered viral vectors in both academia and industry for over 20 years.

Publication Date

August, 2014

Topics Covered

Manufacturing of Viral Gene Therapy Vectors... more

TOPICS COVERED IN THIS TALK

  • Manufacturing of Viral Gene Therapy Vectors
  • Different types of vector production systems
  • Concepts for the design of viral vector production cells
  • Specific viral vector production systems for adenovirus, adeno-associated virus, gamma-retrovirus, and lentivirus
  • Downstream processing
  • Regulatory considerations

Series

Gene Transfer and Gene Therapy

OTHER TALKS IN THIS SERIES

PRINCIPLES AND GENERAL THEMES
Play '1. Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome - Part 1 of 2'
1. Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome - Part 1 of 2 More info
Prof. Luigi Naldini
UG 

TOPICS COVERED IN THIS TALK

  • Gene therapy
  • Key elements in gene transfer
  • Viral infection
  • Cell entry
  • Viral replication
  • Creating a viral vector
  • Therapeutic activity
  • Therapeutic activity after cell division
  • Clinical gene therapy: ex vivo and in vivo milestones
  • Advancing gene therapy: the challenges
  • Limitations of expression cassette
  • Properties & limitations of transfer vector
Play '2. Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome - Part 2 of 2'
2. Gene transfer strategies: principles, state-of-the-art and the major barriers that need to be overcome - Part 2 of 2 More info
Prof. Luigi Naldini
UG 

TOPICS COVERED IN THIS TALK

  • Hazards of transfer vectors
  • Acute exposure to vector particles
  • Hazards for viral and integrating vectors
  • Immune responses to gene transfer (to vector components and to transgene product
  • Types of gene transfer vectors/systems (viral and non-viral)
  • Challenges to clinical translation
Now Playing
Play '4. The host response: adaptive immune response to viral vector delivery'
4. The host response: adaptive immune response to viral vector delivery More info
Prof. Roland W. Herzog
UG 

TOPICS COVERED IN THIS TALK

  • Gene therapy using viral vector
  • Risk of immune responses specific to vector or transgene product
  • Pre-existing immunity to viral vectors due to natural infection
  • Design of vectors to minimize or entirely avoid B and T cell responses
  • Modification of gene transfer protocols to minimize/avoid/circumvent B and T cell responses
MAJOR GENE TRANSFER PLATFORMS AND GENE THERAPY STRATEGIES
Play '5. Lentiviral vectors: design, biological properties, milestones and current major applications, hazards - Part 1 of 2'
5. Lentiviral vectors: design, biological properties, milestones and current major applications, hazards - Part 1 of 2 More info
Prof. Luigi Naldini
UG 

TOPICS COVERED IN THIS TALK

  • Properties of retroviral vectors: Genetic stability in target cells, Transgene expression, Fidelity of replication, Target cell spectrum, Transdution efficiency, Toxicity, RCR or WT virus contamination, Integration, Immunogenicity
  • Innate immune recognition of retroviral vectors
  • Lentiviral vectors
  • Nuclear import of viral genome
  • Challenges of developing lentiviral vectors
  • Viral vector design
  • Design of HIV-based vectors
  • Third generation lentiviral vectors
  • Lentiviral vector composition
  • Lentiviral gene transfer
  • Reducing HIV content of packaging system
  • Self-inactivating transfer vectors
  • HIV vector transcription in HIV-1 infected cells
  • Lentiviral vector biosafety
  • Lentiviral vectors: risk of insertional mutagenesis
Play '6. Lentiviral vectors: design, biological properties, milestones and current major applications, hazards - Part 2 of 2'
6. Lentiviral vectors: design, biological properties, milestones and current major applications, hazards - Part 2 of 2 More info
Prof. Luigi Naldini
UG 

TOPICS COVERED IN THIS TALK

  • Lentiviral vectors: applications, gene transfer efficiency and transgene expression
  • Therapeutic potential of HSC gene therapy
  • Vector integration site analysis
  • Lentiviral-mediated HSC gene transfer
  • Rationale for HSC gene therapy vs. BMT
  • HSC gene transfer by LV: current issues
  • Restriction factors for lentiviral gene transfer
  • Ex vivo transduction by lentiviral vectors
  • HSC gene transfer by LV: current goals
  • Applications: ex vivo into hematopoietic stem cells, ex vivo into lymphocytes, In vivo gene transfer (liver and CNS)
  • Systemic delivery of LV: current issues
  • Direct LV injection into the CNS
  • CNS gene transfer: current issues
Play '7. Gene therapy and gene transfer: vector integration preferences and integration site analysis'
7. Gene therapy and gene transfer: vector integration preferences and integration site analysis More info
Prof. Frederic Bushman

TOPICS COVERED IN THIS TALK

  • Introduction: human gene therapy with integrating vectors
  • Methods for monitoring gene transfer
  • HIV integration targeting
  • Gammaretroviral integration targeting
  • Analysis of vector integration in human gene therapy
Play '8. Surface-mediated targeting of lentiviral vectors'
8. Surface-mediated targeting of lentiviral vectors More info
Prof. Dr. Christian Buchholz

TOPICS COVERED IN THIS TALK

  • In vivo and ex vivo gene therapy
  • Cell entry modes of retroviral vectors
  • Molecular functions of viral envelope proteins
  • Introduction to surface targeting
  • Targeting subtypes of lymphocytes and hematopoietic stem cells (Ex vivo)
  • In vivo targeting (local vs. systemic administration)
Play '9. Tracking vector insertion sites to explore the biology of transduced cells in vivo'
9. Tracking vector insertion sites to explore the biology of transduced cells in vivo More info
Prof. Dr. Christof Von Kalle

TOPICS COVERED IN THIS TALK

  • Clonal marking by integrating vectors
  • Integration site analysis by LAM-PCR
  • Analysis of gene therapy clinical trials for X-SCID, X-CGD, ADA-SCID & Cancer
  • Avoiding oncogenesis in gene therapy
  • Gene therapy for Wiskott-Aldrich Syndrome (WAS)
  • Characterization & understanding of pathogenesis
  • Integrations in known proto-oncogenes
  • Possible triggers of AML development
  • Safer vector systems & new technologies
  • Lentiviral SIN-vectors
  • Influence of vector type on clinical outcome
  • LV integration site analysis: X-ALD trial
  • Repopulation of hematopoietic system
  • Targeted genome modification: nucleases
  • Specificity of DNA modification by ZFN
  • The TALEN nuclease and how it performs
Play '10. Hematopoietic stem cell gene therapy for the treatment of metachromatic leukodystrophy'
10. Hematopoietic stem cell gene therapy for the treatment of metachromatic leukodystrophy More info
Dr. Alessandra Biffi

TOPICS COVERED IN THIS TALK

  • Metachromatic Leukodystrophy (MLD)
  • Hematopoietic stem cell therapy (HCT) for lysosomal storage disorders (LSDs)
  • Improving HCT efficacy
  • The role of brain pre-conditioning
  • Mechanisms of microglia turnover
  • Gene therapy (GT) & enzyme release
  • Gene therapy in murine models
  • HSC gene therapy for MLD
  • Lentivirus integration site analysis
  • Stem cells analysis
  • ARSA activity and delivery to the CNS
  • Cerebral and peripheral demyelination
  • Motor function testing (GMFM)
Play '11. Directed evolution of novel adeno-associated viral vectors for gene therapy'
11. Directed evolution of novel adeno-associated viral vectors for gene therapy More info
Prof. David Schaffer
UG 

TOPICS COVERED IN THIS TALK

  • Recent successes in gene therapy
  • Problems in the field with naturally derived vectors
  • Directed evolution as an approach to engineer optimal viral vector variants that meet clinical needs
  • Examples: development of variants to evade neutralizing antibodies and evolution for enhanced delivery in the retina
Play '12. Gene therapy for Hemophilia'
12. Gene therapy for Hemophilia More info
Prof. Katherine High

TOPICS COVERED IN THIS TALK

  • Hemophilia treatment past and present
  • Gene transfer for genetic disease
  • Viruses engineered to deliver genes
  • Gene therapy using integrating vectors
  • Adeno-associated virus (AAV) structure and composition
  • AAV-Factor IX vectors
  • AAV-mediated gene transfer for hemophilia
  • Risk of germline transmission
  • Peptide library based on AAV and Factor IX
  • Transaminitis and liver enzymes
  • Neutralizing antibodies to AAV
  • Self-complementary DNA and Factor IX synthesis
  • Strategies to overcome immunity to AAV
  • Use of empty capsids
Play '13. Gene therapy for the muscular dystrophies'
13. Gene therapy for the muscular dystrophies More info
Prof. Jeff Chamberlain

TOPICS COVERED IN THIS TALK

  • Introduction to the muscular dystrophies
  • Duchenne muscular dystrophy (DMD)
  • Dystrophin, the gene product of the DMD locus
  • The molecular basis of DMD
  • Strategies for the development of DMD therapies
  • Adeno-associated viral (AAV) vectors and micro-dystrophins
  • Scaling gene therapies to large animal models
  • Exon skipping therapies
Play '14. Helper-dependent adenoviral vectors for gene therapy'
14. Helper-dependent adenoviral vectors for gene therapy More info
Prof. Nicola Brunetti-Pierri

TOPICS COVERED IN THIS TALK

  • Overview of gene therapy vectors
  • Helper-Dependent Ad (HDAd) vector
  • Liver and lung directed gene therapy
  • Hemophilia B gene therapy
  • OTC deficiency clinical trial
  • Balloon occlusion catheter-based delivery of HDAd
  • HDAd-mediated CF gene therapy
  • Brain gene therapy
  • HDAd as genetic vaccine
  • HDAd and stem cells
Play '15. HSV vectors: approaches to the treatment of chronic pain'
15. HSV vectors: approaches to the treatment of chronic pain More info
Prof. Joseph C. Glorioso

TOPICS COVERED IN THIS TALK

  • HSV gene therapy for pain
  • Criteria for vector engineering and gene delivery
  • HSV gene expression and HSV vectors
  • Treating pain with opioid peptides
  • Spinal nerve ligation model of neuropathic pain
  • Transduction of lumbar DRG with HSV vector
  • Osteolytic sarcoma studies
  • Clinical trial in terminal cancer patients
  • Effect of glycine on nociceptive behavior
  • Selective vector infection and expression
  • Targeting transgene expression with promoters
  • Gene expression constructs
  • Promoter-regulated expression in embryonic DRG
  • Comparing LAP, CMV & CGRP gene expression
Play '16. Turning genomic junk into treasure: genetic engineering with the Sleeping Beauty transposon system'
16. Turning genomic junk into treasure: genetic engineering with the Sleeping Beauty transposon system More info
Dr. Zoltan Ivics

TOPICS COVERED IN THIS TALK

  • Transposons can be viewed as natural DNA transfer vehicles
  • Transposons are capable of efficient genomic insertion, similar to integrating viruses
  • Transposition can be controlled by conditionally providing the transposase enzyme
  • DNA of interest cloned into a transposon-based vector can be utilized for stable genomic insertion in a regulated and highly efficient manner
  • Transposition opens up many avenues for genome manipulations in vertebrates
  • Generation of transgenic cells and germline-transgenic animals using transposons
  • The Sleeping Beauty synthetic transposon
  • Clinical applications of the Sleeping Beauty system
NEW TECHNOLOGIES FOR SEQUENCE-SPECIFIC EDITING OF GENE EXPRESSION
Play '17. RNAi for neurological diseases'
17. RNAi for neurological diseases More info
Prof. Beverly L. Davidson

TOPICS COVERED IN THIS TALK

  • Repeat expansion diseases
  • Polyglutamine (polyQ) repeat diseases
  • Huntington’s disease
  • Vectors for delivering genetic material to brain
  • AAVs for delivering RNAi for reducing gene expression
  • Artificial miRNAs
  • Testing miHD for efficacy
  • Off-target silencing
  • MRI-guided delivery of AAV into primates
  • HTT suppression
  • Other gain-of function diseases
  • Targeted infusion for broad coverage
  • Silencing ataxin-1
  • Nonallele specific silencing: experimental design
  • Expression and activity of miSCA1

We use cookies on this site to enhance your user experience

By clicking any link on this page you are giving your consent for us to set cookies.